Lyell Immunopharma, Inc.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: US55083R1041

USD

22.64

10.17 (81.56%)

Feb 05

NAS

View all stocks in this country

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Caribou Biosciences, Inc.

Janux Therapeutics, Inc.

Agenus, Inc.

UroGen Pharma Ltd.

Scholar Rock Holding Corp.

Mineralys Therapeutics, Inc.

Edgewise Therapeutics, Inc.

iTeos Therapeutics, Inc.

Aerovate Therapeutics, Inc.

Lyell Immunopharma, Inc.

Nautilus Biotechnology, Inc.

Why is Lyell Immunopharma, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Lyell Immunopharma, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Lyell Immunopharma, Inc.

-100.0%

0.83

1792.13%

S&P 500

13.99%

0.81

19.85%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-71.63%

EBIT Growth (5y)

2.04%

EBIT to Interest (avg)

-218.23

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.87

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

56.38%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.56

EV to EBIT

0.46

EV to EBITDA

0.50

EV to Capital Employed

-2.39

EV to Sales

-103.99

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-56.34%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

OPERATING PROFIT(Q)

Highest at USD -41.5 MM

PRE-TAX PROFIT(Q)

Highest at USD -40.26 MM

NET PROFIT(Q)

Highest at USD -40.26 MM

EPS(Q)

Highest at USD -2.89

-4What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -171.48 MM

ROCE(HY)

Lowest at -76.59%

Here's what is working for Lyell Immunopharma, Inc.

Operating Profit

Highest at USD -41.5 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD -40.26 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -40.26 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -2.89

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Here's what is not working for Lyell Immunopharma, Inc.

Operating Cash Flow

Lowest at USD -171.48 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)